SUN PHARMACEUTICAL INDUSTRIES LIMITED announced the United States FDA approval of its latest medication on August 26, marking a strategic entry into the U.S. market that is expected to drive significant revenue growth for the global generic leader. The anticipated approval signals a positive impact on the company’s pipeline pipeline and strengthens its foothold in early 2026.